Cargando…

Regression in polypoidal choroidal vasculopathy treated with ziv-aflibercept monotherapy – short term study

PURPOSE: The aim of this study was to evaluate the effectiveness of intravitreal ziv-aflibercept (IVZ) in the treatment of polypoidal choroidal vasculopathy (PCV) and its efficacy in regard to polyp regression using optical coherence tomography (OCT) and indocyanine green angiography (ICGA). METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mishra, Sai B., Singh, Sumit R., Goyal, Prakhar, Chakurkar, Renuka, Govindhari, Vishal, Goud, Abhilash, Chhablani, Jay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982949/ https://www.ncbi.nlm.nih.gov/pubmed/35391816 http://dx.doi.org/10.4103/1319-4534.337857

Ejemplares similares

Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
por: Singh, Sumit Randhir, et al.
Publicado: (2019)

Pachydrusen in polypoidal choroidal vasculopathy in an Indian cohort
por: Singh, Sumit Randhir, et al.
Publicado: (2019)

Commentary: Ziv-aflibercept: An alternative antivascular endothelial growth factor agent for polypoidal choroidal vasculopathy
por: Anshuman, Kumar, et al.
Publicado: (2019)

Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
por: Miyakubo, Tomoko, et al.
Publicado: (2023)

Intravitreal bevacizumab monotherapy for treatment-naive polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar, et al.
Publicado: (2014)

Intravitreal bevacizumab monotherapy for treatment-naïve polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar, et al.
Publicado: (2013)

Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2020)

One year outcomes of eyes with polypoidal choroidal vasculopathy with ≥20/40 visual acuity treated with anti-vascular endothelial growth factor agents
por: Singh, Sumit R., et al.
Publicado: (2022)

Disadvantages of photodynamic therapy for polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar
Publicado: (2010)

Treatment of polypoidal choroidal vasculopathy with intravitreal bevacizumab monotherapy
por: Tan, Colin S H, et al.
Publicado: (2013)

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura, Masahiro, et al.
Publicado: (2013)

Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
por: Lee, Sang Eun, et al.
Publicado: (2019)

Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy
por: Arakawa, Akira, et al.
Publicado: (2017)

Ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: A retrospective comparison of clinical outcomes and cost at 1 year
por: Singh, Sumit Randhir, et al.
Publicado: (2020)

Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage
por: Mansour, Ahmad M., et al.
Publicado: (2020)

Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy
por: Ma, I-Hsin, et al.
Publicado: (2021)

Treatment of polypoidal choroidal vasculopathy by photodynamic therapy, aflibercept and dexamethasone triple therapy
por: Ho, Mary, et al.
Publicado: (2016)

Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience
por: Bansal, Aditya, et al.
Publicado: (2017)

Retinal pigment epithelium rip following single intravitreal ziv-aflibercept injection
por: Singh, Sumit Randhir, et al.
Publicado: (2018)

Choroidal structure as a biomarker for visual acuity in intravitreal aflibercept therapy for polypoidal choroidal vasculopathy
por: Asano, Shotaro, et al.
Publicado: (2018)

Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion
por: Braimah, Imoro Z, et al.
Publicado: (2019)

Latest Developments in Polypoidal Choroidal Vasculopathy: Epidemiology, Etiology, Diagnosis, and Treatment
por: Chaikitmongkol, Voraporn, et al.
Publicado: (2020)

Low incidence of pachydrusen in central serous chorioretinopathy in an Indian cohort
por: Singh, Sumit Randhir, et al.
Publicado: (2020)

Comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience
por: Kathiriya, Vidhi, et al.
Publicado: (2018)

One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity
por: Kwon, Ji Min, et al.
Publicado: (2021)

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2021)

Short-Term Efficacy in Polypoidal Choroidal Vasculopathy Patients Treated With Intravitreal Aflibercept or Conbercept
por: Xue, Yin, et al.
Publicado: (2022)

Polypoidal choroidal vasculopathy in a case of retinitis pigmentosa, successfully treated with intravitreal aflibercept
por: Takahashi, Nana, et al.
Publicado: (2021)

Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy
por: Jeon, Young-Joon, et al.
Publicado: (2021)

Anti-vascular endothelial growth factor drugs in polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar
Publicado: (2011)

Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients
por: Nawar, Amin E., et al.
Publicado: (2020)

Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy
por: Vyas, Chinmayi Himanshuroy, et al.
Publicado: (2021)

Polypoidal Choroidal Vasculopathy in Asians
por: Wong, Chee Wai, et al.
Publicado: (2015)

Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2017)

Reply to comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience
por: Bansal, Aditya, et al.
Publicado: (2018)

Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
por: Nishikawa, Keiichi, et al.
Publicado: (2019)

One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
por: Weng, Hsin-Yu, et al.
Publicado: (2019)

One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy
por: Tamachi, Tomoko, et al.
Publicado: (2020)

Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK
por: Ogura, Yuichiro, et al.
Publicado: (2022)

Choroidal Nevus in an Eye with Polypoidal Choroidal Vasculopathy
por: Asao, Kazunobu, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_btehebgij79bjda712f7edm4gu